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Abstract 
The Oregon ‘‘Death With Dignity’’ Act (DWD Act) allows a terminally ill patient with 
6 months to live to ask a physician for medication to end their life. To receive the 
medication, the DWD Act requires the patient to verbally request the prescription 
twice 2 weeks apart as well as in writing. Patients with amyotrophic lateral sclero-
sis have three main barriers to using DWD: (a) the ability to communicate their in-
formed consent as the disease progresses further, (b) the possibility of dementia 
which may affect their decisional capacity, and (c) given the nature and speed of 
amyotrophic lateral sclerosis, limited time is available for patients to self-adminis-
ter the prescription and may rush the time line for the death. This article reviews 
the current knowledge and addresses the need for adjustments to existing law and 
recommendations for states considering a DWD law. 
Keywords:  United States, amyotrophic lateral sclerosis, death with dignity, compe-
tency, informed consent, physician-assisted suicide 
Introduction 
The Oregon ‘‘Death with Dignity’’ Act (DWD Act) allows physicians to pre-
scribe medication allowing patients with a terminal illness end their lives. 
For patients with amyotrophic lateral sclerosis (ALS), however, the barriers 
digitalcommons.unl.edu
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to using the DWD Act may be difficult to overcome. ALS, also known as Lou 
Gehrig’s disease, is a degenerative disease of the nervous system which af-
fects the brain and spinal cord (National Institute of Neurological Disorders 
and Stroke [NINDS], 2013) for which no treatment or cure has been identi-
fied (Mehta et al., 2016). The degeneration and eventual death of these mo-
tor neurons effectively cuts off communication from the brain to the mus-
cles and can lead to the loss of the ability to move, eat, speak, and eventually 
breathe (NINDS, 2013). The progressive loss of function is fatal (Mehta et al., 
2016). Patients with ALS (PALS) have three main barriers to using DWD: (a) 
the ability to communicate their informed consent as the disease progresses 
further, (b) the possibility of dementia which may affect their decisional ca-
pacity, and (c) given the nature and speed of ALS, limited time is available 
for patients to self-administer the prescription and may rush the time line 
for the death. The research presented in this article will address the need 
for adjustments to be made to the current law in states with DWD laws and 
recommendations for other states considering a DWD law. 
Death With Dignity 
History of the Oregon DWD Act 
The Oregon DWD Act passed by a small margin in 1994 but not without pro-
test (Cohen-Almagor & Hartman, 2001). Groups such as the American Med-
ical Association and the Catholic Church opposed the DWD Act, the former 
due to the role the physician played in prescribing life-ending medication 
and the latter due to the perceived disrespect of the gift of life (Cohen-Al-
magor & Hartman, 2001). After the DWD Act passed, one of the most im-
portant responses was in the form of a lawsuit filed in federal district court 
which challenged the Act based on the 14th Amendment to the Constitu-
tion. The lawsuit claimed violation of due process and equal protection of 
vulnerable patients who may choose to utilize physician-assisted suicide 
due to coercion or undiagnosed mental disorders (Cohen-Almagor & Hart-
man, 2001). In 1997, the Supreme Court ruled there was no constitutional 
right to assisted suicide, and the Oregon Legislature placed the measure to 
repeal the Oregon DWD Act on the November 1997 ballot (Cohen-Alma-
gor & Hartman, 2001). The citizens of Oregon voted to keep the DWD Act 
in place by a wider margin than originally voted for the DWD Act in 1994 
(Cohen-Almagor & Hartman, 2001). 
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Requirements of the Oregon DWD Act 
The Oregon DWD Act allows terminally ill patients in the state of Oregon 
with a life expectancy of 6 months or less to request and receive prescrip-
tions for self-administered life-ending medications from their physician (Co-
hen- Almagor & Hartman, 2001; OR. Rev. Stat. 127.800-127.995, 1999). An 
important part of the law is the self-administered requirement—it does not 
legalize or ‘‘authorize a physician or any other person to end a patient’s life 
by lethal injection, mercy killing or active euthanasia’’ (Cohen-Almagor & 
Hartman, 2001; OR. Rev. Stat. 127.800-127.995, 1999). A capable and com-
petent resident of Oregon with a diagnosis of a terminal disease (e.g., ALS) 
can request ‘‘medication for ending his or her life in a humane and digni-
fied manner’’ (Cohen- Almagor & Hartman, 2001; OR. Rev. Stat. 127.800-
127.995, 1999). The DWD Act includes a provision protecting physicians from 
civil and criminal liability in aiding a person in the act of committing suicide, 
which outside of the DWD Act violates Oregon law (OR. Rev. Stat. 127.800-
127.995, 1999; Cohen-Almagor & Hartman, 2001). The DWD Act does not 
require a physician to write the prescription for the lethal medication; how-
ever, if a patient requests the medication and the physician refuses, the pa-
tient does have a right to transfer care to another provider and the physi-
cian must provide the medical records to the new physician (OR. Rev. Stat. 
127.800-127.995, 1999). 
The DWD Act provides meticulous detail of the procedures required for 
both patients and physicians under the Act (OR. Rev. Stat. 127.800-127.995, 
1999). Several steps are required prior to the prescription of the life-end-
ing medication. First, the attending physician must make the determination 
that the patient is terminally ill. The terminally ill diagnosis means the dis-
ease is incurable and irreversible, and in the physician’s reasonable medi-
cal judgment, will cause the patient’s death within 6 months (OR. Rev. Stat. 
127.800-127.995, 1999). The patient must make an oral request for assis-
tance in ending their life in a humane and dignified way, at which time the 
patient’s attending physician would make the determination of competency, 
mental health status, and the capability of self-administering the medica-
tion (OR. Rev. Stat. 127.800-127.995, 1999). The attending physician counsels 
the patient to ensure an informed decision, including advising the patient 
of the risks, results of taking the medication if prescribed, and alternative 
care options (e.g., hospice, palliative care). The attending physician is re-
quired to recommend the patient inform the next-of-kin of their decision 
to utilize the DWD Act. Furthermore, the physician will refer the patient to 
counseling if they suspect a mental health condition such as depression or 
issues with the patient’s competency or capability of self-administering the 
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medication (OR. Rev. Stat. 127.800-127.995, 1999). Next, the patient is re-
quired to make a request in writing, witnessed by at least one person who 
is not related by blood, not the attending physician, health-care provider, 
owner of a health-care facility, or entitled to any part of the patient’s estate 
(OR. Rev. Stat. 127.800-127.995, 1999). The patient is referred to and seen 
by a consulting physician to confirm the diagnosis and the length of survival 
time calculated by the attending physician. The consulting physician verifies 
the patient is competent, is capable of self-administering the lethal medi-
cation, is acting voluntarily, and has made an informed decision (OR. Rev. 
Stat. 127.800-127.995, 1999). If the consulting physician feels that there is a 
concern about mental health conditions (e.g., depression, dementia), they 
would recommend counseling and no medication would be prescribed un-
til the counselor determines the mental health status and competency of 
the patient (OR. Rev. Stat. 127.800-127.995, 1999). The patient is required 
to make a second verbal request no sooner than 15 days after the first ver-
bal request (OR. Rev. Stat. 127.800-127.995, 1999). At that time the attend-
ing physician must offer the opportunity for the patient to rescind the orig-
inal request; however, the patient may rescind the request at any point in 
the process (OR. Rev. Stat. 127.800-127.995, 1999). The prescription for the 
medication cannot be written any less than 15 days after the first verbal re-
quest, and no less than 48 hours after the written request has been com-
pleted (OR. Rev. Stat. 127.800-127.995, 1999). The physician then contacts 
the pharmacist to inform him or her of the prescription, and once received, 
the pharmacist will dispense the medication either to the patient, the attend-
ing physician, or a designated agent of the patient (OR. Rev. Stat. 127.800- 
127.995, 1999). The patient may decide to use the medication at any time 
to end their life in a humane and dignified way. 
Amyotrophic Lateral Sclerosis 
ALS Phenotypes and Diagnosis 
ALS is rare, affecting only 5.0 per 100,000 persons per year (Mehta et al., 
2016). In limb onset ALS, the affected person has weakness in either the af-
fected hand or foot, leading to tripping (drop foot) or difficult with grasp-
ing objects (drop wrist). Bulbar onset ALS leads to difficulties with speech 
and swallowing (Kiernan et al., 2011; Muscular Dystrophy Association [MDA] 
2016a; NINDS, 2013). Furthermore, there are atypical presentations includ-
ing weight loss (an indicator of poor prognosis), cramping and twitching of 
the muscles without weakness or wasting, unstable emotions, and frontal–
temporal dementia (Kiernan et al., 2011). 
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ALS diagnosis is made by means of elimination. In addition, because of 
the uncertain nature of the ALS diagnosis, there are several diagnostic cate-
gories that patients may fit into. Arguments have been made that the diag-
nostic criteria are too restrictive and may have poor sensitivity, limiting di-
agnosis in the earliest stages when patients would most likely benefit from 
therapeutic intervention (Kiernan et al., 2011). Late diagnosis can prevent 
the successful navigation of medical and psychosocial interventions. ALS di-
agnosis can be a devastating blow to both the patient and family members, 
and indecision about and insensitivity of the delivery of the final diagnosis 
may delay coping with and acceptance of the diagnosis (Kiernan et al., 2011). 
ALS Prognosis 
ALS progression is incessant, with 50% of patients dying within 30 to 36 
months of diagnosis, and 20% surviving between 5 and 10 years after di-
agnosis (Kiernan et al., 2011). Reduced length of survival is associated with 
bulbar onset, older age, and early involvement of the respiratory muscles 
(Kiernan et al., 2011). Increase length of survival is associated with diag-
nostic delay, younger age, and limb onset (Kiernan et al., 2011). Only two 
drugs, newly released Radicava and Riluzole, have been developed to treat 
ALS. Riluzole is thought to extend the life span by 3 months (ALS Associa-
tion, 2016). 
The earliest stages of ALS often happen prior to diagnosis (MDA, 2016b). 
Muscles begin to either atrophy or spasticity begins to develop, and cramps 
or fasciculations begin. The patient may notice fatigue, balance problems, 
slurred speech, trouble gripping objects, and trouble with tripping. As ALS 
progresses into the middle stages, symptoms become more prevalent and 
paralysis of muscle groups begins, while other muscles begin to weaken 
and atrophy and fasciculations continue (MDA, 2016b). Contractures can 
develop in unused muscles; swallowing can become more problematic and 
lead to choking and difficulty eating. Greater assistance is needed; driving 
is often given up and falls may occur from which the patient cannot return 
to standing without assistance. The respiratory muscles begin to weaken, 
leading to shortness of breath, especially when lying down. In late stage ALS, 
paralysis is widespread requiring assistance for most activities and needs 
(MDA, 2016b). Eating, drinking, and speech may become impossible. Respi-
ratory muscles are compromised, which can cause sleepiness, unclear think-
ing, headaches, and an increase risk of pneumonia. Most deaths from ALS 
are due to respiratory insufficiency leading to respiratory failure which pro-
gresses over the course of the disease (MDA, 2016b). Less commonly, death 
may occur due to aspiration of food or saliva, pulmonary embolism, cardiac 
arrhythmias, and malnutrition (MDA, 2016b). 
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The Statement of the Problem 
There is concern that the Oregon DWD Act (as well as others) may be has-
tening the death or unintentionally extending the life PALS due to the re-
quirements set forth in the Act itself. The DWD Act requires that the patient 
ingests the medication on their own either through swallowing the medica-
tion or through a percutaneous endoscopic gastronomy or radioscopically 
inserted percutaneous tube. In addition, the DWD Act requires the patient 
to verbally request the prescription for the lethal medication twice 2 weeks 
apart as well as in writing in-between the two verbal requests. Furthermore, 
the DWD Act requires the patient to have less than 6 months to live. 
The requirements for physician-assisted suicide are difficult to meet for 
PALS, who have a varied disease course and an uncertain time line to death. 
PALS must rely on computer-generated speech as the disease progresses, 
due to the weakening of the facial muscles, which if not successfully mas-
tered may render the patient unable to verbally communicate their desire 
for physician-assisted suicide. Furthermore, PALS lose the ability to swallow 
and face progressive paralysis which can hamper both the ability to request 
physician-assisted suicide in writing and self-administer the medication. The 
loss of the ability to swallow and move may happen prior to the 6-month 
guideline provided in the DWD Act. Moreover, PALS may develop cognitive 
impairment as the disease progresses (e.g., frontotemporal dementia, lan-
guage deficits), which would no longer allow them to be deemed compe-
tent to request the medication under the DWD Act. Research estimates that 
cognitive impairment may develop in 35.6% to 50% of PALS over the course 
of the disease (Khin, Minor, Holloway, & Pelleg, 2015). Cognitive impairment 
does not necessarily mean a patient is no longer competent; however, the 
multiplicative losses over the course of the disease may make the determi-
nation of competency in the last 6 months of life difficult or impossible (Khin 
et al., 2015). To further complicate the determination of competency in PALS, 
research indicates that physicians do not use standardized methods of as-
sessing decision-making capacity in Alzheimer’s patients, which may indi-
cate discrepancies in assessing competency in PALS (Khin et al., 2015; Vo-
licer & Ganzini, 2003). 
There are concerns about the desire for physician-assisted suicide regard-
ing PALS. PALS commonly report psychosocial distress and show symptoms 
of depressed mood, hopelessness, anxiety, and confusion (Connolly, Galvin, 
& Hardiman, 2015; Ganzini & Block, 2002; Gill, 2004; Monforte-Royo et al., 
2011). PALS report feeling as though they are a burden to their families and 
caregivers and a significant increase in loneliness as the disease progresses 
(Achille & Ogloff, 2004; Monforte-Royo et al., 2011; Stutzki et al., 2014). The 
feelings of depression, loneliness, isolation, anxiety, and that the patient is 
a burden on their caregivers have been associated in previous research as 
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increasing the ‘‘wish to hasten death’’ through the use of physician-assisted 
suicide (Achille & Ogloff, 2004; Stutzki et al., 2014). Opponents of the DWD 
Act believe that these feelings may hasten death unnecessarily (Ganzini & 
Block, 2002). 
Moreover, PALS may feel extreme anger if denied physician-assisted sui-
cide due to suspected mental instability, resulting from the patient feeling 
powerless rather than their life is valued and hampering opportunities to re-
solve unrelated emotional issues (Ganzini & Block, 2002). Families may feel 
that the physician, acting in the role of the gatekeeper, is an insurmountable 
barrier to receiving a prescription and misinterpreting their concern for the 
patient as the patient being ignored or dismissed (Ganzini & Block, 2002). 
Physician–patient communication may be too focused in the here and now 
rather than on future needs, neglect the negative aspects of disease progres-
sion, and who the communication needs to be initiated by (e.g., neurologist, 
primary care, and palliative care) may not be clear to the care team, increas-
ing the risk the patient feels unheard (Moss et al., 1996). Physicians and in-
surance companies also act as gatekeepers of the treatments and equipment 
desired by PALS, and fighting the system of bureaucracy to obtain needed 
items may feel like an added burden to the patient and their family, increas-
ing the desire for a hastened death (Reagan et al., 2003). Physicians further 
express concerns that patients who request physician-assisted suicide later 
in the disease course are doing so because of poorly managed symptoms 
and fear of death (Ganzini & Block, 2002). 
Previous Policy Recommendations and Alternative Solutions 
In recognition of the difficulties faced by PALS, Oregon House Bill 3337 
(2015) sought to modify the language of the DWD Act to extend the ex-
pected time until death from 6 months to 1 year. House Bill 3337 did not 
make it out of committee. Utah, while largely copying the Oregon DWD 
Act when proposing the state’s own DWD Act (Utah House Bill 391, 2015), 
removed the expected time until death language and replaced it with the 
phrase ‘suffering from a terminal disease; or an intractable and unbearable 
illness’ (Utah House Bill 391, 2015). The Utah proposal, however, did not pass 
when voted on. Opponents of the proposed changes to the Oregon DWD 
Act and the Utah DWD Act felt that a 6-month time until death was an im-
portant safeguard for the patient requesting access to a prescription for life-
ending medication. While unsuccessful, the bills introduced in Oregon and 
Utah have highlighted important limitations of DWD laws. 
In addition to legislative efforts to modify DWD policy, physicians and 
others have suggested that improvements in both hospice and palliative care 
should alleviate the need for the DWD Act. Physicians believe hospice and 
J.  A .  Andersen  in  OMEGA—Journal  of  Death  and Dy ing  ( 2018 )       8
palliative care will allow patients to receive adequate pain control, counsel-
ing for the patient and their caregivers to alleviate fear and anxiety, and ac-
cess to home care staff to relieve the perceived burden of the patient’s ill-
ness (Achille & Ogloff, 2004; Ganzini & Block, 2002; Monforte-Royo, 2011; 
Moss et al., 1996; Reagan et al., 2003; Stutzki et al., 2014). Proponents of 
the DWD Act disagree, as it removes the patient’s choice to have a digni-
fied death of their choosing, rather than the unbearable suffering brought 
on by terminal illness. 
Policy Recommendations 
While the extended time line to death, as seen in the proposed amend-
ment to the Oregon DWD Act (2015), and the language change to ‘‘suffer-
ing from a terminal disease; or an intractable and unbearable illness’’ sug-
gested in the proposed Utah DWD Act (Utah House Bill 391, 2015) have 
not been implemented, these changes are necessary to ensure equal ac-
cess for PALS to physician-assisted suicide. Given the uncertainty of ALS 
progression and when the ability to speak, write, and swallow will be lost 
to the PALS, ensuring adequate time to request and receive the medication 
from the doctor while a patient’s health is still intact is vital for this group. 
In addition, extending the time line or modifying the language of such 
bills allows for patients with other conditions with uncertain progression 
paths (e.g., Alzheimer’s) to use the DWD Act. Modifications may be sug-
gested for specific disease diagnoses to leave in place safeguards for pa-
tients with terminal illness that are more predictable in nature. In addition, 
conversations between lawmakers and PALS may allow lawmakers to bet-
ter understand this extremely rare disease. Moreover, policy makers need 
to understand ALS more thoroughly to better assess future amendments 
to DWD Acts currently in place as well as DWD Acts under consideration. 
For PALS, hastening death out of fear that the medication may not be self-
administrable is a real concern. Clarifying the language of DWD Acts to al-
low for percutaneous endoscopic gastronomy or radioscopically inserted 
percutaneous tube administration, as well as the ability for the patient to 
begin administering the medication and allow for a trained person to fin-
ish administering it, may allow patients fearful of missing their window for 
physician-assisted suicide more peace of mind and allow for them to delay 
death for additional time with their loved ones. It may also allow for ad-
ditional time to provide intervention such as palliative care, home health 
care, and hospice or respite care for caregivers to be put into place, pos-
sibly increasing the quality of life for PALS and decreasing the use of the 
life-ending medication in this population. 
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Given the issues of physician–patient communication, medical schools 
need to require additional training for their staff and students on how to 
discuss terminal illness and the various pathways a terminal illness may take. 
For example, discussion of the typical causes of death (e.g., respiratory fail-
ure) versus the feared cause of death (e.g., choking) may allow patients to 
feel more in control of their treatment course. Exploring options such as 
noninvasive versus invasive ventilation, forgoing the percutaneous endo-
scopic gastronomy or radioscopically inserted percutaneous tube to allow 
a natural death by withholding nutrition and hydration, and acknowledging 
the patient’s possible desire for physician-assisted suicide versus palliative 
care may allow the patient to feel more connected with their physician. The 
opportunity for PALS to see their physician as a partner, rather than a gate-
keeper, may in turn allow PALS to be more open to possible options for care. 
Moreover, ensuring that physicians understand the patient needs, and deals 
with them proactively by ordering equipment (e.g., wheelchairs, computer-
assisted voice programs), ahead of the point of need may help the patient 
retain autonomy and control over their situation. These actions may reduce 
the need for, as well as the use of, physician- assisted suicide. Physicians, 
however, must be aware in the states where DWD Acts have been passed 
that their patients may request physician-assisted suicide and should pre-
pare themselves to listen to the patient’s request and handle it appropriately. 
Implementing a standard assessment of cognitive abilities, thereby en-
suring patients are evaluated equally by physicians, is an important aspect 
of improving the DWD Act in Oregon and other states that have imple-
mented similar laws. The use of a standardized system of evaluating com-
petency will reduce some of the pressure felt by physicians to make the cor-
rect decisions regarding the request for life-ending medications. In turn, a 
standardized method to assess competency may allow the patient to avoid 
feelings of anger and allow them to work through the emotional and psy-
chosocial issues barring them from receiving their prescriptions. Future re-
search around ALS and DWD may need to focus on the areas of competency 
more thoroughly to better understand the possible implications of compe-
tency testing and may help physicians and families better understand the 
disease progression and issues of competency. 
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